Business Context and Reporting Period
Company: TopSpin Medical, Inc. (Note: Request metadata listed "My Size, Inc." but the filing text identifies the registrant as TopSpin Medical, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2008
Business Overview: TopSpin is a development-stage company incorporated in Delaware with operations conducted through its Israeli subsidiary. The company develops miniaturized MRI sensors for medical imaging. Historically focused on an intravascular MRI catheter (IVMRI) for cardiology, the company shifted focus in April 2008 to a urology product for prostate cancer diagnosis. Due to severe financial constraints, the company suspended all operational activities and terminated the majority of its workforce in October 2008.
Key Financial Metrics
| Metric | 2008 (NIS) | 2008 (USD Approx.) | 2007 (NIS) |
|---|---|---|---|
| Revenue | 0 | $0 | 0 |
| Net Loss | (20,150,000) | ($5,299,842) | (24,168,000) |
| Operating Cash Flow | (25,398,000) | ($6,680,168) | (33,732,000) |
| Cash and Equivalents (Year End) | 3,385,000 | $890,321 | 40,978,000 |
| Total Assets | 4,391,000 | $1,154,918 | 51,274,000 |
| Total Liabilities | 5,188,000 | $1,364,545 | 52,317,000 |
| Accumulated Deficit | (180,441,000) | ($47,459,495) | (165,670,000) |
Note: USD conversions based on the exchange rate of NIS 3.8020 per USD as of December 31, 2008, as stated in the filing.
Material Changes vs. Prior Period
- Operational Suspension: In October 2008, the company suspended all R&D and commercial activities and terminated all employees except for the finance department and those on maternity leave.
- Debt Settlement: The company settled its Series A Debentures (NIS 50,000,000 principal) by converting them into 450,000,000 shares of common stock and paying a cash settlement of NIS 12,513,000 (approx. $3.29 million). This significantly depleted cash reserves.
- Asset Reduction: Total assets decreased by approximately 91% from 2007 to 2008, primarily due to the cash outflow for the debt settlement and the sale/write-off of engineering and technical equipment.
- Expense Reduction: Net loss decreased by 17% compared to 2007, driven by a 39% reduction in gross R&D expenses and a 62% reduction in marketing and sales expenses following the suspension of activities.
- Regulatory Status: The company withdrew its FDA marketing application for the IVMRI Catheter in July 2008, and its CE Marks were cancelled in December 2008 due to non-participation in annual testing.
Outlook, Risks, and Contingencies
- Liquidity Risk: The company has no revenue and relies on financing to continue. Management believes current cash resources are sufficient for limited operations for at least 12 months, but there is no assurance of obtaining additional funding required to resume regular business.
- Going Concern: The company has an accumulated deficit of NIS 180.4 million and has not achieved profitable operations. Continued operations are dependent on raising additional capital or acquiring new business lines.
- Government Grants: The company expects to receive grants from the Office of the Chief Scientist (OCS) of Israel for 2007 and 2008 expenses but has not received them in the expected timeframe. Uncertainty regarding these funds contributed to the suspension of activities.
- Subsequent Financing: In February 2009, the company raised NIS 900,000 (approx. $236,717) through a private placement of common stock and warrants.
- Contingent Liabilities: The company has a potential tax provision of NIS 1,344,000 related to the bond settlement and royalty obligations to the OCS upon future commercialization.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the NIS 3.385 million cash balance against the company's stated ability to fund operations for 12 months given the suspended status.
- Grant Receivables: Confirm the status of the outstanding OCS grants (approx. NIS 3.2 million for 2008 expenses) and the likelihood of collection.
- Debt Settlement Impact: Review the dilution impact of the 450 million shares issued to bondholders, which resulted in bondholders holding approximately 71% of the outstanding capital stock.
- Regulatory Hurdles: Assess the feasibility of restarting clinical trials and obtaining FDA/CE approvals given the cancellation of previous marks and the withdrawal of the FDA application.
- Management Continuity: Note the resignation of the CEO (Yaron Tal) in October 2008 and the subsequent management structure, as the board is currently managing day-to-day operations.